FANCJ promotes PARP1 activity during DNA replication that is essential in BRCA1 deficient cells

Nat Commun. 2024 Mar 23;15(1):2599. doi: 10.1038/s41467-024-46824-5.


The effectiveness of poly (ADP-ribose) polymerase inhibitors (PARPi) in creating single-stranded DNA gaps and inducing sensitivity requires the FANCJ DNA helicase. Yet, how FANCJ relates to PARP1 inhibition or trapping, which contribute to PARPi toxicity, remains unclear. Here, we find PARPi effectiveness hinges on S-phase PARP1 activity, which is reduced in FANCJ deficient cells as G-quadruplexes sequester PARP1 and MSH2. Additionally, loss of the FANCJ-MLH1 interaction diminishes PARP1 activity; however, depleting MSH2 reinstates PARPi sensitivity and gaps. Indicating sequestered and trapped PARP1 are distinct, FANCJ loss increases PARPi resistance in cells susceptible to PARP1 trapping. However, with BRCA1 deficiency, the loss of FANCJ mirrors PARP1 loss or inhibition, with the detrimental commonality being loss of S-phase PARP1 activity. These insights underline the crucial role of PARP1 activity during DNA replication in BRCA1 deficient cells and emphasize the importance of understanding drug mechanisms for enhancing therapeutic response.

MeSH terms

  • Cell Line, Tumor
  • DNA Helicases* / genetics
  • DNA Repair
  • DNA Replication*
  • Fanconi Anemia Complementation Group Proteins* / genetics
  • Humans
  • MutS Homolog 2 Protein / genetics
  • Poly (ADP-Ribose) Polymerase-1* / metabolism
  • S Phase


  • DNA Helicases
  • MutS Homolog 2 Protein
  • Poly (ADP-Ribose) Polymerase-1
  • BRIP1 protein, human
  • PARP1 protein, human
  • Fanconi Anemia Complementation Group Proteins